Reata Announces Clinical Trial Design for FALCON, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of ADPKD
Reata Management Call to Discuss Phase 3 ADPKD Study Design
PHOENIX was an open-label, multicenter, phase 2 US trial designed to evaluate the safety, tolerability, and efficacy of bardoxolone methyl in four separate patient cohorts. The target enrollment is 25 to 30 patients per cohort.